[HTML][HTML] Defining the vulnerable patient with myeloma—a frailty position paper of the European Myeloma Network
G Cook, A Larocca, T Facon, S Zweegman… - Leukemia, 2020 - nature.com
As the treatment landscape continues to evolve towards the application of precision
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network
G Cook, A Larocca, T Facon, S Zweegman… - …, 2020 - pubmed.ncbi.nlm.nih.gov
As the treatment landscape continues to evolve towards the application of precision
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
Defining the vulnerable patient with myeloma—a frailty position paper of the European Myeloma Network
G Cook, A Larocca, T Facon… - …, 2020 - researchinformation.amsterdamumc …
As the treatment landscape continues to evolve towards the application of precision
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
Defining the vulnerable patient with myeloma--a frailty position paper of the European Myeloma Network.
G Cook, A Larocca, T Facon, S Zweegman… - Leukemia, 2020 - go.gale.com
As the treatment landscape continues to evolve towards the application of precision
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network.
G Cook, A Larocca, T Facon, S Zweegman… - Leukemia, 2020 - europepmc.org
As the treatment landscape continues to evolve towards the application of precision
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
Defining the vulnerable patient with myeloma—a frailty position paper of the European Myeloma Network
G Cook, A Larocca, T Facon, S Zweegman… - LEUKEMIA, 2020 - iris.unito.it
As the treatment landscape continues to evolve towards the application of precision
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
[HTML][HTML] Defining the vulnerable patient with myeloma—a frailty position paper of the European Myeloma Network
G Cook, A Larocca, T Facon, S Zweegman… - Leukemia, 2020 - ncbi.nlm.nih.gov
As the treatment landscape continues to evolve towards the application of precision
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network.
G Cook, A Larocca, T Facon, S Zweegman… - Leukemia, 2020 - europepmc.org
As the treatment landscape continues to evolve towards the application of precision
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
[PDF][PDF] Deining the vulnerable patient with myeloma—a frailty position paper of the European Myeloma Network
G Cook, A Larocca, T Facon, S Zweegman… - 2020 - iris.unito.it
As the treatment landscape continues to evolve towards the application of precision
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …